Stenotrophomonas maltophilia is an aerobic gram-negative bacillus that most commonly causes infection in immune-compromised hospitalized individuals, especially those with hematologic malignancy, neutropenia, and history of treatment with broad-spectrum antibiotics. This infection has been known to affect multiple organ systems, but cutaneous involvement has been increasingly recognized over the years, albeit still relatively rare. Here we report a case of ulcerations on the palm and wrist, which were found to be positive for S. maltophilia. We also review the various skin and mucocutaneous findings that have been reported with this organism as well as treatment for this often multiple drug resistant organisms.
Introduction
Stenotrophomonas maltophilia is a gram-negative bacillus with both aerobic and anaerobic capabilities and is associated with nosocomial and community-acquired infections [1] . Initially thought to be a relative of Pseudomonas, and classified as Pseudomonas maltophilia, it was later recognized as its own species of the genus Stenotrophomonas. The organism primarily causes infections in immune-compromised patients, frequently via colonization of synthetic devices and machinery [2] . Clinically, S. maltophilia can cause bacteremia, endocarditis and respiratory, urinary, ophthalmologic, and central nervous system infections, as well as skin and soft tissue infections, as we describe in the case below [1, 3] .
Case Report
Dermatology was consulted in the inpatient setting to evaluate ulcerations on the wrist of a 68-year-old Panamanian male present for at least one week (Figure 1 ). The patient had originally been admitted approximately one month prior for dehydration, increasing weakness, diabetic ketoacidosis and acute kidney injury. He was soon after transferred to the intensive care unit due to multiorgan failure and was treated with 3 weeks of linezolid and ceftriaxone for MRSA pneumonia and a urinary tract infection. Past medical history included prostate cancer and diabetes mellitus. 
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Discussion
S. maltophilia can cause a variety of mucocutaneous findings. Vartivarian described five patients with S. maltophilia-related primary cellulitis, mostly associated with catheter use, as well as six patients with metastatic cellulitis [2] . Cellulitis-like lesions of the legs and chest have also been described in three additional patients, likely due to septic emboli [4] . Ecthyma gangrenosum has been reported in association with S. maltophilia infection in a patient with a recent allogeneic bone marrow transplantation [5] . Mucocutaneous infections, as seen here, have also been noted, with ulcerations described on the lips, gingiva, and buccal mucosa [2] . Non-healing leg and foot ulcers and digital skin ulcer associated with the pathogen have also been described [6] [7] [8] .
Hospitalized patients who are immunocompromised are at greatest risk of developing infection with S. maltophilia, though cases in immunocompetent individuals have rarely been described [6, 8] . Most occur in the setting of malignancy, particularly hematologic cancers being treated with chemotherapy. Other risk factors include administration of broad-spectrum antibiotics and use of intravenous catheters, mechanical ventilation or tracheotomy [3, 4, 6, 9, 10] .
The route of infection is not entirely known, but it seems that the organism invades via damaged skin and mucous membranes, or colonization of venous catheters, and then spreads hematogenously [2, 4, 10] . Recovery is dependent upon early recognition of the infection and treatment with effective antibiotics [1, 10] . S. maltophilia has become resistant to many broad-spectrum antimicrobial agents, including beta-lactams, carbapenems and aminoglycosides; therefore, the current therapy of choice is TMP-SMX, due to its activity against most strains of the bacterium. Removal of all associated invasive synthetic devices is also critical [2] .
It is important that S. maltophilia be considered in the differential diagnosis of a skin or soft tissue infection in an immunocompromised patient with malignancy, particularly due to its high resistance to therapy. Our case contributes to the growing body of knowledge regarding skin manifestations attributed to S. maltophilia infection, and highlights the need to consider this pathogen when presented with an ulcer of unknown etiology in an immunocompromised patient.
